Action EPRSQ EPIRUS BIOPHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues EPIRUS Biopharmaceuticals, Inc.

Actions

EPRSQ

US29428P1075

Temps Différé OTC Markets
Autres places de cotation
 20:34:32 06/02/2024 		Varia. 5j. Varia. 1 janv.
- USD -.--% Graphique intraday de EPIRUS Biopharmaceuticals, Inc. -.--% -.--%
2016 Transcript : EPIRUS Biopharmaceuticals, Inc., Q4 2015 Earnings Call, Mar 15, 2016
2015 Transcript : EPIRUS Biopharmaceuticals, Inc., Q3 2015 Earnings Call, Nov 16, 2015

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.
Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q).
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.
Praxis Precision Medicines, Inc. agreed to acquire Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q) for $1 million.
Notice of Intent of Asset Sale Filed by EPIRUS Biopharmaceuticals, Inc.
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from S&P TMI Index
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from NASDAQ Composite Index
EPIRUS Biopharmaceuticals, Inc. Announces Management Resignations
EPIRUS Biopharmaceuticals, Inc. Filed for Bankruptcy
EPIRUS Biopharmaceuticals, Inc. Announces Executive Termination
Polpharma S.A. completed the acquisition of EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc..
Polpharma S.A. entered into a binding term sheet to acquire EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc. for $3.5 million.
EPIRUS Biopharmaceuticals, Inc. Announces Executive Changes
EPIRUS Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
EPIRUS Biopharmaceuticals, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015
EPIRUS Biopharmaceuticals, Inc. Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)
EPIRUS Biopharmaceuticals, Inc Provides Clinical Program Update on BOW015
EPIRUS Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
EPIRUS Biopharmaceuticals, Inc. Appoints Vincent E. Aurentz as Chief Business Officer
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action EPRSQ
  4. Actualités EPIRUS Biopharmaceuticals, Inc.
  5. Autres langues